S1 Ep3: The Gene-Editing Company That Didn't Need CRISPR

CRISPR, TALEN, and gene editing sound like the stuff of the future, but they are already changing medicine. What about zinc finger nucleases? That's what Sangamo Therapeutics uses to perform gene editing, and the tech recently earned the company a $3 billion deal. Today on Data Book, the origins of CRISPR and the Sangamo story.